- Home
- GOEV vs BLRX Comparison
GOEV vs BLRX Comparison
Compare GOEV & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOEV
- BLRX
- Stock Information
- Founded
- GOEV 2017
- BLRX 2003
- Country
- GOEV United States
- BLRX Israel
- Employees
- GOEV N/A
- BLRX N/A
- Industry
- GOEV
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GOEV
- BLRX Health Care
- Exchange
- GOEV Nasdaq
- BLRX Nasdaq
- Market Cap
- GOEV 34.3M
- BLRX 36.0M
- IPO Year
- GOEV N/A
- BLRX 2011
- Fundamental
- Price
- GOEV $0.50
- BLRX $0.48
- Analyst Decision
- GOEV Strong Buy
- BLRX Strong Buy
- Analyst Count
- GOEV 6
- BLRX 2
- Target Price
- GOEV $22.71
- BLRX $11.50
- AVG Volume (30 Days)
- GOEV 8.8M
- BLRX 407.5K
- Earning Date
- GOEV 11-13-2024
- BLRX 11-29-2024
- Dividend Yield
- GOEV N/A
- BLRX N/A
- EPS Growth
- GOEV N/A
- BLRX N/A
- EPS
- GOEV N/A
- BLRX N/A
- Revenue
- GOEV $1,864,000.00
- BLRX $17,048,000.00
- Revenue This Year
- GOEV $2,999.89
- BLRX N/A
- Revenue Next Year
- GOEV $1,016.40
- BLRX N/A
- P/E Ratio
- GOEV N/A
- BLRX N/A
- Revenue Growth
- GOEV 259.15
- BLRX N/A
- 52 Week Low
- GOEV $0.37
- BLRX $0.39
- 52 Week High
- GOEV $8.81
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- GOEV 36.38
- BLRX 53.32
- Support Level
- GOEV $0.48
- BLRX $0.40
- Resistance Level
- GOEV $0.76
- BLRX $0.46
- Average True Range (ATR)
- GOEV 0.11
- BLRX 0.03
- MACD
- GOEV 0.01
- BLRX 0.01
- Stochastic Oscillator
- GOEV 24.32
- BLRX 94.50
About GOEV Canoo Inc.
Canoo Inc is a mobility technology company providing with a proprietary modular electric vehicle platform and connected services initially focused on commercial fleet, government and military customers. The Company has developed a breakthrough EV platform that it believes will enable it to rapidly iterate and bring new products, addressing multiple use cases, to market faster than competition and at lower cost.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.